These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21999177)

  • 1. Aflibercept (VEGF-TRAP): the next anti-VEGF drug.
    Stewart MW
    Inflamm Allergy Drug Targets; 2011 Dec; 10(6):497-508. PubMed ID: 21999177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aflibercept in wet AMD: specific role and optimal use.
    Semeraro F; Morescalchi F; Duse S; Parmeggiani F; Gambicorti E; Costagliola C
    Drug Des Devel Ther; 2013; 7():711-22. PubMed ID: 23990705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aflibercept for age-related macular degeneration: a game-changer or quiet addition?
    Browning DJ; Kaiser PK; Rosenfeld PJ; Stewart MW
    Am J Ophthalmol; 2012 Aug; 154(2):222-6. PubMed ID: 22813448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration.
    Papadopoulos Z
    Eur J Ophthalmol; 2019 Jul; 29(4):368-378. PubMed ID: 30813810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.
    Stewart MW
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):103-13. PubMed ID: 23473589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aflibercept: newly approved for the treatment of macular edema following central retinal vein occlusion.
    Evoy KE; Abel SR
    Ann Pharmacother; 2013 Jun; 47(6):819-27. PubMed ID: 23673531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Management of aflibercept in routine clinical practice].
    Cabrera López F
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():29-34. PubMed ID: 25925049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aflibercept: an update on recent milestones achieved.
    Palejwala NV; Lauer AK
    Drugs Today (Barc); 2014 Dec; 50(12):779-90. PubMed ID: 25588083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
    Deissler HL; Lang GK; Lang GE
    Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
    Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
    Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
    Yuzawa M; Fujita K; Wittrup-Jensen KU; Norenberg C; Zeitz O; Adachi K; Wang EC; Heier J; Kaiser P; Chong V; Korobelnik JF
    Ophthalmology; 2015 Mar; 122(3):571-8. PubMed ID: 25439429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of VEGF in diseases of the retina].
    Barquet LA
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications.
    Akiyode O; Major J; Ojo A
    J Pharm Pract; 2017 Oct; 30(5):534-540. PubMed ID: 27166390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF-Trap is a potent modulator of vasoregenerative responses and protects dopaminergic amacrine network integrity in degenerative ischemic neovascular retinopathy.
    Rojo Arias JE; Economopoulou M; Juárez López DA; Kurzbach A; Au Yeung KH; Englmaier V; Merdausl M; Schaarschmidt M; Ader M; Morawietz H; Funk RHW; Jászai J
    J Neurochem; 2020 May; 153(3):390-412. PubMed ID: 31550048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
    Yazdi MH; Faramarzi MA; Nikfar S; Falavarjani KG; Abdollahi M
    Expert Opin Biol Ther; 2015; 15(9):1349-58. PubMed ID: 26076760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal aflibercept for neovascular age-related macular degeneration.
    Xu D; Kaiser PK
    Immunotherapy; 2013 Feb; 5(2):121-30. PubMed ID: 23413903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
    MacDonald DA; Martin J; Muthusamy KK; Luo JK; Pyles E; Rafique A; Huang T; Potocky T; Liu Y; Cao J; Bono F; Delesque N; Savi P; Francis J; Amirkhosravi A; Meyer T; Romano C; Glinka M; Yancopoulos GD; Stahl N; Wiegand SJ; Papadopoulos N
    Angiogenesis; 2016 Jul; 19(3):389-406. PubMed ID: 27234973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.